This article, published in The Journal of Infectious Diseases, discusses a study of antibody persistence and immunological priming for two formulations of a meningococcal group C (menC) conjugate (MCC) vaccine administered at 2, 3, and 4 months of age by boosting vaccine recipients at age 13 to 16 months or 4 years with 10 micrograms of unconjugated menC polysaccharide vaccine. The study demonstrated immunological memory at four years of age in children receiving MCC vaccine on the United Kingdom's two-/three-/four-month immunization schedule.

Author(s): Borrow R, Goldblatt D, Andrews N, et al.

Published: 2002

Resource types: Peer-reviewed journal

Diseases: Meningococcus

Topics: Disease/vaccine specific information

Regions: North America and Europe